AstraZeneca Broadens Oncology Portfolio Through Summit Deal -- Market Talk
Dow Jones2026/09/29 05:490548 GMT - AstraZeneca's agreement with Summit Therapeutics will help the U.K. drugmaker broaden its immuno-oncology portfolio without going all-in, RBC Capital Markets analysts say in a research note. AstraZeneca is investing $2 billion in the Miami-based biotech and entering into a research collaboration centered on ivonescimab, Summit's experimental cancer drug that blocks two proteins--called PD-1 and VEGF--that help tumors grow and evade the immune system. AstraZeneca's investments in this space lacked a so-called PD-1xVEGF asset like ivonescimab, RBC says. Each company retains its development and commercial rights for their assets, which likely signals AstraZeneca believes its own approaches are superior to PD-1xVEGF, the analysts say. Nevertheless, the deal leaves the door open for a potential expansion with Summit in the future, they add. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
September 29, 2026 01:49 ET (05:49 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Production Increase Falls Short, Layoffs First! Boeing (BA.US) Cuts 5% of Commercial Airplane Jobs, Delays 737 Monthly Production Target of 47 Aircraft to 2027
Stephanie Pope, head of Boeing's commercial airplanes division, informed employees in an internal memo on Monday that due to obstacles in increasing aircraft production, the division plans to cut 5% of its workforce.
After acquiring SpotHero, Uber (UBER.US) makes its debut in the parking sector with a parking space reservation feature, initially available in 15 U.S. cities
Uber has launched a brand new parking space reservation feature, which marks its first step in the parking sector following its acquisition of the parking app SpotHero earlier this year.
Crypto prices
More
